Axial spondyloarthritis
V Navarro-Compán, A Sepriano… - Annals of the …, 2021 - ard.bmj.com
Axial spondyloarthritis (axSpA) encompasses both radiographic and non-radiographic
axSpA. It is a chronic inflammatory disease with a predilection for involving the axial …
axSpA. It is a chronic inflammatory disease with a predilection for involving the axial …
Ankylosing spondylitis: etiology, pathogenesis, and treatments
Ankylosing spondylitis (AS), a common type of spondyloarthropathy, is a chronic
inflammatory autoimmune disease that mainly affects spine joints, causing severe, chronic …
inflammatory autoimmune disease that mainly affects spine joints, causing severe, chronic …
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
S Ramiro, E Nikiphorou, A Sepriano… - Annals of the …, 2023 - ard.bmj.com
Objectives To update the Assessment of SpondyloArthritis international Society (ASAS)-
EULAR recommendations for the management of axial spondyloarthritis (axSpA). Methods …
EULAR recommendations for the management of axial spondyloarthritis (axSpA). Methods …
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind …
A Deodhar, PS Helliwell, WH Boehncke, AP Kollmeier… - The Lancet, 2020 - thelancet.com
Background Many patients with psoriatic arthritis have an inadequate response to tumor
necrosis factor (TNF) inhibitors. Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via …
necrosis factor (TNF) inhibitors. Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via …
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Objectives Janus kinase inhibitors (JAKi) have been approved for use in various immune-
mediated inflammatory diseases. With five agents licensed, it was timely to summarise the …
mediated inflammatory diseases. With five agents licensed, it was timely to summarise the …
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
L Gossec, X Baraliakos, A Kerschbaumer… - Annals of the …, 2020 - ard.bmj.com
Objective To update the European League Against Rheumatism (EULAR) recommendations
for the pharmacological treatment of psoriatic arthritis (PsA). Methods According to the …
for the pharmacological treatment of psoriatic arthritis (PsA). Methods According to the …
EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis
R Geenen, CL Overman, R Christensen… - Annals of the …, 2018 - ard.bmj.com
Pain is the predominant symptom for people with inflammatory arthritis (IA) and osteoarthritis
(OA) mandating the development of evidence-based recommendations for the health …
(OA) mandating the development of evidence-based recommendations for the health …
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a …
PJ Mease, JS Smolen, F Behrens, P Nash… - Annals of the …, 2020 - ard.bmj.com
Objectives To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic …
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
M Kostine, A Finckh, CO Bingham, K Visser… - Annals of the …, 2021 - ard.bmj.com
Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given …
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given …
Treating juvenile idiopathic arthritis to target: recommendations of an international task force
Recent therapeutic advances in juvenile idiopathic arthritis (JIA) have made remission an
achievable goal for most patients. Reaching this target leads to improved outcomes. The …
achievable goal for most patients. Reaching this target leads to improved outcomes. The …